Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

"I know physicians are busy, but I’m treating a patient, not a disease. I take a holistic approach. I think we need to make physicians who treat chronic myeloid leukemia treat the disease and make ...

We recently published 10 Market Stars Behind Millionaire-Making in 2025. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the top performers. Terns Pharmaceuticals climbed by 629.64 percent in 2025 ...

The major molecular response rate was 68% with asciminib and 49% with IS-TKIs (difference, 19% [95% CI, 10-28]; P .001). The Food and Drug Administration (FDA) has granted accelerated approval to ...

It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...

CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026Planned milestones include pivotal dose selection, ...

Scemblix showed a 68% major molecular response rate at 48 weeks, outperforming tyrosine kinase inhibitors by 19%. Common side effects included rash, musculoskeletal pain, and fatigue, with laboratory ...